Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) have been given a consensus recommendation of “Moderate Buy” by the ten analysts that are currently covering the stock, Marketbeat reports. Four research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $43.33.

ARWR has been the subject of several research analyst reports. Chardan Capital reissued a “buy” rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a report on Thursday, December 12th. Sanford C. Bernstein decreased their target price on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating for the company in a research note on Friday, November 29th. Citigroup dropped their price target on Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 27th. StockNews.com upgraded Arrowhead Pharmaceuticals to a “sell” rating in a research report on Friday, December 20th. Finally, Piper Sandler dropped their target price on shares of Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating on the stock in a report on Wednesday, November 27th.

Arrowhead Pharmaceuticals Trading Up 5.0 %

NASDAQ:ARWR opened at $19.68 on Wednesday. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 2.06. Arrowhead Pharmaceuticals has a 1-year low of $17.05 and a 1-year high of $36.72. The firm has a market capitalization of $2.46 billion, a price-to-earnings ratio of -3.92 and a beta of 0.95. The business’s 50-day moving average price is $20.85 and its two-hundred day moving average price is $21.56.

Insider Activity at Arrowhead Pharmaceuticals

In other news, insider James C. Hamilton sold 32,729 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $19.82, for a total transaction of $648,688.78. Following the completion of the transaction, the insider now owns 272,122 shares in the company, valued at approximately $5,393,458.04. This represents a 10.74 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Patrick O’brien sold 29,184 shares of Arrowhead Pharmaceuticals stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $19.82, for a total transaction of $578,426.88. Following the completion of the transaction, the chief operating officer now owns 535,201 shares of the company’s stock, valued at $10,607,683.82. The trade was a 5.17 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 147,432 shares of company stock valued at $2,957,986 over the last ninety days. Corporate insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. R Squared Ltd purchased a new position in shares of Arrowhead Pharmaceuticals in the fourth quarter worth about $38,000. Values First Advisors Inc. bought a new position in Arrowhead Pharmaceuticals during the 3rd quarter worth approximately $52,000. Van ECK Associates Corp increased its stake in Arrowhead Pharmaceuticals by 72.3% in the 4th quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 1,250 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in Arrowhead Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock worth $88,000 after purchasing an additional 788 shares during the period. Finally, KBC Group NV lifted its position in Arrowhead Pharmaceuticals by 45.9% in the fourth quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 1,644 shares during the last quarter. 62.61% of the stock is currently owned by institutional investors.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.